Conduction system disease in cardiac amyloidosis

Trends Cardiovasc Med. 2024 May;34(4):250-253. doi: 10.1016/j.tcm.2023.02.004. Epub 2023 Feb 17.

Abstract

Cardiac amyloidosis (CA) has diverse and deleterious effects on the conductive system. Atrial fibrillation is by far the most common electrophysiological manifestation of CA and is associated with more mortality, morbidity, and hospitalizations. While AF increases the risk of thrombosis regardless of the CHA2DS2-VASc score, the risk of thromboembolism seems to be high even in CA patients without AF. AV Nodal disease is prevalent and may precede the diagnosis of CA. The incidence of ventricular arrhythmias remains disputed, and the role of implantable cardioverter defibrillator devices in CA patients is controversial. Newer therapies targeted against specific types of CA have been developed, but their effects on conductive system disease are not well studied.

Publication types

  • Review

MeSH terms

  • Action Potentials
  • Amyloidosis* / diagnosis
  • Amyloidosis* / physiopathology
  • Amyloidosis* / therapy
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy
  • Cardiac Conduction System Disease* / diagnosis
  • Cardiac Conduction System Disease* / physiopathology
  • Cardiac Conduction System Disease* / therapy
  • Cardiomyopathies / diagnosis
  • Cardiomyopathies / physiopathology
  • Cardiomyopathies / therapy
  • Defibrillators, Implantable
  • Electric Countershock / adverse effects
  • Electric Countershock / instrumentation
  • Heart Conduction System / physiopathology
  • Heart Rate / drug effects
  • Humans
  • Prognosis
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome